Despite the great success of the OMP regulation (2000) and of the Paediatric Regulation (2006), concerns about remaining unmet needs, patient access, affordability, and sustainability of pharmaceutical spending have risen in the past few years. In particular, there are concerns about the appropriateness of the current regulatory framework to attain the societal goal of reducing unmet needs while ensuring value-for-money.
As a result, the European Commission is examining the strengths and shortcomings of both Regulations, with the view to recalibrate policy. Building on fresh evidenced brought by two reports that EFPIA developed in collaboration with Dolon and OHE, this virtual event seeks to discuss challenges and facilitators in the development of orphan and paediatric medicines.
Join the conversation to outline ways forward towards lowering the remaining unmet needs.
Simone Boselli, Public Affair Director, EURORDIS
Nathalie Moll, Director General, EFPIA
Giles Platford, President, Europe & Canada, Takeda
Carmelo Rizzari, President-Elect, SIOP Europe
Andrzej Rys, Director responsible for Health Systems, medical products and innovation, DG SANTE